Which has higher valuation and earnings, VTRS or PFE?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.38 -$3.51B -$0.26 N/A Pfizer $62.58B 2.19 $7.77B $1.31 18.35

Is VTRS or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Pfizer 11.83% 19.44% 8.41%

Does the media favor VTRS or PFE?

In the previous week, Pfizer had 22 more articles in the media than Viatris. MarketBeat recorded 32 mentions for Pfizer and 10 mentions for Viatris. Viatris' average media sentiment score of 0.92 beat Pfizer's score of 0.65 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 18 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better valuation & earnings, VTRS or ARGX?

argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viatris $14.30B 1.38 -$3.51B -$0.26 N/A argenex $4.25B 13.47 $1.29B $22.46 40.96

Is VTRS or ARGX more profitable?

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 44.37% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% argenex 31.31% 44.37% 37.55%

Does the media favor VTRS or ARGX?

In the previous week, Viatris had 4 more articles in the media than argenex. MarketBeat recorded 10 mentions for Viatris and 6 mentions for argenex. Viatris' average media sentiment score of 0.92 beat argenex's score of 0.47 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAK or VTRS?

Viatris has a consensus target price of $17.50, suggesting a potential upside of 3.18%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Viatris 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media favor TAK or VTRS?

In the previous week, Viatris had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Viatris and 4 mentions for Takeda Pharmaceutical. Viatris' average media sentiment score of 0.92 beat Takeda Pharmaceutical's score of -0.07 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or VTRS?

In the previous week, Revolution Medicines had 13 more articles in the media than Viatris. MarketBeat recorded 23 mentions for Revolution Medicines and 10 mentions for Viatris. Viatris' average media sentiment score of 0.92 beat Revolution Medicines' score of 0.49 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or VTRS?

In the previous week, Viatris had 5 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 10 mentions for Viatris and 5 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.69 beat Viatris' score of 0.92 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Viatris 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viatris (VTRS) Competitors

$16.96 +0.16 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$17.01 +0.05 (+0.29%)

As of 07:52 PM Eastern

Compare

VTRS vs. PFE, ARGX, TAK, RVMD, and TEVA

Should you buy Viatris stock or one of its competitors? MarketBeat compares Viatris with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viatris include Pfizer (PFE), argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "medical" sector.

How does Viatris compare to Pfizer?

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A
Pfizer	$62.58B	2.19	$7.77B	$1.31	18.35

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 3.18%. Pfizer has a consensus target price of $28.59, suggesting a potential upside of 18.93%. Given Pfizer's higher probable upside, analysts plainly believe Pfizer is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pfizer	2 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.20

Pfizer has a net margin of 11.83% compared to Viatris' net margin of -2.04%. Pfizer's return on equity of 19.44% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Pfizer	11.83%	19.44%	8.41%

Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.2%. Viatris pays out -184.6% of its earnings in the form of a dividend. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Pfizer had 22 more articles in the media than Viatris. MarketBeat recorded 32 mentions for Pfizer and 10 mentions for Viatris. Viatris' average media sentiment score of 0.92 beat Pfizer's score of 0.65 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	18 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Pfizer beats Viatris on 14 of the 19 factors compared between the two stocks.

How does Viatris compare to argenex?

Viatris (NASDAQ:VTRS) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A
argenex	$4.25B	13.47	$1.29B	$22.46	40.96

In the previous week, Viatris had 4 more articles in the media than argenex. MarketBeat recorded 10 mentions for Viatris and 6 mentions for argenex. Viatris' average media sentiment score of 0.92 beat argenex's score of 0.47 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 3.18%. argenex has a consensus target price of $1,037.61, suggesting a potential upside of 12.79%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has a net margin of 31.31% compared to Viatris' net margin of -2.04%. argenex's return on equity of 44.37% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
argenex	31.31%	44.37%	37.55%

Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Summary

argenex beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Viatris compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. Takeda Pharmaceutical pays out 123.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -184.6% of its earnings in the form of a dividend.

Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
Viatris	-2.04%	19.04%	7.62%

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.91	-$1.01B	$0.39	43.47
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

Viatris has a consensus target price of $17.50, suggesting a potential upside of 3.18%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Viatris had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Viatris and 4 mentions for Takeda Pharmaceutical. Viatris' average media sentiment score of 0.92 beat Takeda Pharmaceutical's score of -0.07 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Viatris beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks.

How does Viatris compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Revolution Medicines has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,496.70	-$1.13B	-$7.07	N/A
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

In the previous week, Revolution Medicines had 13 more articles in the media than Viatris. MarketBeat recorded 23 mentions for Revolution Medicines and 10 mentions for Viatris. Viatris' average media sentiment score of 0.92 beat Revolution Medicines' score of 0.49 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines presently has a consensus target price of $142.33, suggesting a potential downside of 25.27%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 3.18%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Viatris	-2.04%	19.04%	7.62%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Revolution Medicines beats Viatris on 11 of the 17 factors compared between the two stocks.

How does Viatris compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

In the previous week, Viatris had 5 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 10 mentions for Viatris and 5 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.69 beat Viatris' score of 0.92 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Viatris	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.31	$1.41B	$1.33	26.07
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, indicating a potential upside of 20.51%. Viatris has a consensus price target of $17.50, indicating a potential upside of 3.18%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Viatris' net margin of -2.04%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Viatris	-2.04%	19.04%	7.62%

Summary

Teva Pharmaceutical Industries beats Viatris on 13 of the 16 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTRS vs. The Competition

Export

Metric	Viatris	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.56B	$9.43B	$7.10B	$12.57B
Dividend Yield	2.86%	1.61%	2.67%	6.89%
P/E Ratio	-65.23	26.45	27.19	24.43
Price / Sales	1.38	18.32	578.09	116.19
Price / Cash	2.28	114.48	49.34	57.41
Price / Book	1.33	6.21	10.95	6.40
Net Income	-$3.51B	$177.20M	$3.56B	$331.37M
7 Day Performance	6.80%	3.34%	1.77%	-0.48%
1 Month Performance	6.80%	10.45%	6.65%	3.39%
1 Year Performance	84.35%	15.22%	36.06%	24.97%

Viatris Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTRS Viatris	2.8999 of 5 stars	$16.96 +1.0%	$17.50 +3.2%	+81.6%	$19.56B	$14.30B	N/A	30,000
PFE Pfizer	4.5089 of 5 stars	$24.40 +0.4%	$28.82 +18.2%	-6.7%	$138.44B	$62.58B	18.62	75,000	Trending News Analyst Downgrade
ARGX argenex	3.9961 of 5 stars	$912.46 +2.8%	$1,023.39 +12.2%	+68.7%	$55.17B	$4.25B	40.63	1,863	Analyst Upgrade
TAK Takeda Pharmaceutical	1.5597 of 5 stars	$15.97 +0.3%	N/A	+8.7%	$50.63B	$28.32B	40.94	47,455	Analyst Downgrade
RVMD Revolution Medicines	1.6837 of 5 stars	$192.62 +5.8%	$132.78 -31.1%	+413.5%	$38.71B	$11.58M	N/A	250	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTRS) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viatris (VTRS) Competitors

VTRS vs. PFE, ARGX, TAK, RVMD, and TEVA

How does Viatris compare to Pfizer?

Summary

How does Viatris compare to argenex?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Summary

How does Viatris compare to Revolution Medicines?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viatris (VTRS) Competitors

VTRS vs. PFE, ARGX, TAK, RVMD, and TEVA

How does Viatris compare to Pfizer?

Which has higher valuation and earnings, VTRS or PFE?

Do analysts recommend VTRS or PFE?

Is VTRS or PFE more profitable?

Which has more volatility and risk, VTRS or PFE?

Do insiders and institutionals hold more shares of VTRS or PFE?

Is VTRS or PFE a better dividend stock?

Does the media favor VTRS or PFE?

Summary

How does Viatris compare to argenex?

Which has better valuation & earnings, VTRS or ARGX?

Does the media favor VTRS or ARGX?

Do insiders and institutionals have more ownership in VTRS or ARGX?

Do analysts prefer VTRS or ARGX?

Is VTRS or ARGX more profitable?

Which has more risk and volatility, VTRS or ARGX?

Summary

How does Viatris compare to Takeda Pharmaceutical?

Is TAK or VTRS a better dividend stock?

Which has more risk and volatility, TAK or VTRS?

Is TAK or VTRS more profitable?

Which has higher earnings and valuation, TAK or VTRS?

Do analysts rate TAK or VTRS?

Does the media favor TAK or VTRS?

Do institutionals & insiders hold more shares of TAK or VTRS?

Summary

How does Viatris compare to Revolution Medicines?

Which has preferable valuation and earnings, RVMD or VTRS?

Does the media favor RVMD or VTRS?

Do analysts rate RVMD or VTRS?

Which has more risk and volatility, RVMD or VTRS?

Is RVMD or VTRS more profitable?

Do insiders & institutionals believe in RVMD or VTRS?

Summary

How does Viatris compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or VTRS?

Which has stronger valuation & earnings, TEVA or VTRS?

Do analysts rate TEVA or VTRS?

Do institutionals & insiders believe in TEVA or VTRS?

Which has more risk and volatility, TEVA or VTRS?

Is TEVA or VTRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTRS vs. The Competition

Viatris Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools